The concentration of dehydroepiandrosterone sulphate (DHEAS) was measured in the plasma of 104 patients aged 16-78 years (48 men) undergoing routine assessment of anterior pituitary reserve. A fasting plasma sample was collected at 0900 h on the same day that either an insulin tolerance test or a glucagon stimulation test was performed. Serum cortisol, DHEAS and prolactin were measured by radioimmunoassay. DHEAS levels between 0·5 and 14nmoi/L were significantly but negatively correlated with age but there was no significant correlation with basal cortisol, maximum stimulated cortisol, the increment in cortisol or basal prolactin. The correlation of DHEAS with age was also observed when results for women were analysed separately but this did not hold for men. For male and female results separately, there was again no correlation of basal DHEAS with basal cortisol, maximum stimulated cortisol, increment of cortisol or basal prolactin.
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Dehydroepiandrosterone sulphate (DHEAS) is the most abundant circulating adrenal sterioid in adult life. Levels are generally 15-20% higher in men than women, partly due to a minor contribution of dehydroepiandrosterone (DHA) and DHEAS secretion from the testis':' and to a lower in vivo cleavage of DHEAS in men compared to women." Although DHA is secreted in the free form by the adrenal, much of it is sulphated in the liver and indeed some is secreted as DHEAS by the adrenal.' Adrenal androgen secretion begins in utero and increases at the adrenarche (about 6-8 years of age). Circulating DHEAS levels increase through puberty to reach a peak in both sexes in the late teens to early twenties, before gradually declining again to low levels by the age of 70. 4-7 The precise physiological role of DHEAS is unknown although it appears to constitute a water soluble reservoir of DHA which can be desulphated to become biologically active. I Adrenal androgen secretion, including DHA Correspondence: Dr S M Shalet, and DHEAS, is predominantly under the control of adrenocorticotrophin (ACTH)2,8,9 but other postulated hormonal influences include gonadotrophins," prolactin.Y':" a putative adrenal androgen stimulating hormone" and a variety of peptides derived from proopiomelanocortin (pOMC). 14, 15 Basal measurements of adrenal steroid concentrations have been advocated as a simple and non-invasive means of assessing hypothalamicpituitary adrenal function. 5,16-18 Primary adrenal failure leads to a fall in adrenal androgen secretion" and this is also seen in patients with secondary adrenal insufficiency due to long term corticosteroid treatment":" or hypothalamicpituitary disease. 5.2o The secretions of DHA and cortisol show a prominant circadian rhythm consistent with the changes in circulating ACTH levels but the degree of change in circulating DHEAS concentrations during the day is much less." The use of basal DHEAS levels therefore has the theoretical advantage that samples may be taken at any time of the day. However, there has been no adequate comparison of the basal M D Littley et al.
DHEAS level and the cortisol response to provocative testing. We have therefore investigated the usefulness of a basal measurement of DHEAS as a means of predicting the ability of the hypothalamic-pituitary-adrenal axis to respond to stress in patients with pituitary disease.
PATIENTS AND METHODS
One hundred and four unselected patients with suspected or proven pituitary disease undergoing routine assessment of hypothalamic-pituitary function were studied. They were aged between 16 and 78 years and consisted of 48 men and 56 women. Eighty-nine patients had proven pituitary tumours which had been treated by surgery, external radiotherapy or both. Hypopituitarism was suspected in the remaining 15 patients because of symptoms in nine, or previous incidental external radiotherapy to the hypothalamic-pituitary axis in six. Patients with Cushing's disease and those taking corticosteroid replacement were excluded from the study. Women who were taking sex steroid replacement therapy discontinued it 4 weeks before the tests.
All patients underwent a standard insulin tolerance test (ITT; soluble insulin 0·2 U/Kg i.v.) or a glucagon stimulation test (GST; porcine glucagon I mg s.c. or i.m.) in the fasting state, beginning at 0900 h. Adequate hypoglycaemia in patients undergoing the ITT was documented by a fall in blood glucose to less than 2·0 mmol/L, Blood samples were taken before injection for serum cortisol, prolactin and DHEAS. Further samples for cortisol were taken at 30 min intervals for a total of2 h in the ITT or 3 h in the GST.
Serum DHEAS was assayed in duplicate using a commercial radioimmunoassay method (Amersham International, Amersham, UK). Within assay coefficient of variation (CV) was < 10% between O' 7 Jlmol/L and 20 Jlmol/L. Between assay CV was 7-13% in the range 2·1-16 J.lmol/L. Serum cortisol was measured using an in-house radioimmunoassay, with inclusion of I % sodium salicylate in the assay buffer to eliminate binding by corticosteroid-binding plasma proteins. The coefficient of variation between assays was < II % over the range 260-900nmol/L and within assay was < 5% at 330 nmol/L. A normal serum cortisol response to provocative testing is defined as > 500 nmol/L and the laboratory reference range for basal serum cortisol at 0900 h is 250-500 nmol/L. Serum prolactin was measured in duplicate using a radioimmunoassay (NETRIA method) standarized against the reference preparation NIBSC 83/562. Within assay CV was 7% at 230mU/L and between assay CV was 16-17% over the range 230-1500mU/L. The reference range for basal serum prolactin at 0900h is <350mU/L.
In view of the difficulties of obtaining sufficient specimens to determine our own age and sex related reference range for DHEAS, a search of the literature was performed. Using the data of Carlstrom et a1. 4 , Yamaji et al? and Orentreich et al.,6 regression lines for the lower limit of the quoted reference ranges for men and women were derived (Fig. I) . The regression lines had the following formulae;
where y is serum DHEAS (Jlmol/L) and x is age in years.
Statistical tests used were Spearman's rank correlation test and linear regression analysis. ( Fig. 2a, b) . There was a significant negative correlation between serum DHEAS and age for all 104 patients (r = -0-45, P < 0·001) which was also noted when the data for women were analysed separately r = -0,66, P < 0,001) although this correlation did not hold for the data for men when analysed separately (r = -0-25, 0-05 < P < 0,1). There was no significant correlation between the basal serum DHEAS level and either the basal cortisol, peak stimulated Total 27 77 104 cortisol or increment in serum cortisol concentration. Furthermore, there was no significant correlation between the basal serum prolactin concentration and DHEAS level.
RESULTS

Serum
Using the age and sex related reference ranges described above (Fig. 1) , 18 patients were found to have a subnormal DHEAS concentration. However, only eight of these also had a cortisol response to provocative testing of < 500 nmol/L. Eighty-six patients had a normal serum DHEAS concentration but only 67 patients showed serum cortisol responses to an ITT or GST of > 500nmol/L ( Table 1 , Fig. 2a, b) . Thus 19 patients with subnormal cortisol responses to provocative testing had a normal basal serum DHEAS level. Ten of these 19 also had elevation of the serum prolactin level.
DISCUSSION
Due to the difficulty of obtaining sufficient samples from normal subjects to establish a valid age and sex related reference range for DHEAS, we have derived ranges from the published data of Carlstrom et a/., 4 Yamaji et al? and Orentreich et a/. 6 The reference ranges given by these authors were similar although the methods for DHEAS measurement differed. We used a commercial radioimmunoassay for the measurement of DHEAS which utilizes a 125 1 DHEAS label. This assay was validated against our previous 'in house' radioimmunoassay which employed a JH-DHEAS label, and which was comparable with the assays described by Carlstrom et a/., 4 Yamaji et 
al? and Orentreich et al"
Our results indicate that the measurement of basal serum DHEAS on one occasion is a very poor predictor of ACTH deficiency as defined by a subnormal cortisol response to provocative testing. Our findings are thus in contrast to those of Yamaji et al? who measured circulating DHEAS levels in patients with secondary adrenal insufficiency; 80 out of the 84 patients were found to have subnormal DHEAS values compared to normal controls of corresponding age. They concluded that basal DHEAS measurement might be a useful indicator of deficient ACTH secretion and of value in rapid screening of patients for ACTH deficiency. However, their study measured DHEAS levels only in selected patients with secondary adrenal insufficiency documented by more conventional tests, rather than in a more generalized clinical setting. Dunn et a/. 16 and Karalus et a/. 17 also used a random DHEAS measurement to assess adrenal function in an unselected group of asthmatic patients, but found that there was a poor correlation with the results of a short tetracosactrin (Synacthen) test.
A normal serum DHEAS level was found in 19 of 27 patients with subnormal cortisol response to an ITT or GST in our study. A possible explanation for this might be one or more factors other than ACTH which stimulate adrenal androgen secretion. A potential candidate for this factor is prolactin.S":" but the serum prolactin concentration was elevated in only 10 (two men) of these 19 patients indicating that this could not be the only explanation. Little is known about the effects of impaired pituitary function on the relative secretion of ACTH(1-J9) and other POMC-derived peptides. The continued secretion of peptides with more potent adrenal androgen stimulating activity":" might therefore be important in the apparent discordance between cortisol secretion and DHEAS levels observed in our study. A discordance has been reported previously following synthetic ACTH infusion in patients with hypothalamicpituitary disease." However, these authors found relatively greater impairment of DHEAS secretion, suggesting that adrenal androgen production might be more severely affected than cortisol production by impaired ACTH secretion. In addition, androgen secretion was found to return to normal more slowly than cortisol secretion following withdrawal of therapeutic exogenous steroids.
In the present study, of 77 patients with normal cortisol responses 10 had subnormal DHEAS levels. A greater impact of hypopituitarism on adrenal androgen secretion as described by Cutler et a/. 22 might account for this phenomenon. However, if gonadotrophins are also an important stimulus to DHEAS secretion in men," then co-existing gonadotropin deficiency might be expected to reduce DHEAS levels further. However, none of the six men showing subnormal DHEAS with normal cortisol secretion in the present study had evidence of gonadotrophin deficiency.
The decline in circulating DHEAS levels with age in normal individuals and the differences between men and women make the clinical application of basal serum DHEAS measurement as a test of hypothalamic-pituitary-adrenal function very cumbersome. The reference range is an important factor in this respect as the definition of normality clearly affects the discriminant value of the test. However, our results ( Fig. 2a, 2b) suggest that alterations to the lower limit of the reference range for DHEAS would not improve the overall value of the test. The large number of potential variables which might affect DHEAS secretion but which might not be important in cortisol secretion and vice versa make the basal estimation of DHEAS an unreliable measure of the ability of an individual to respondto stress.
